Sinopharm Group China Bio (Northwest) Health Technology, China National Biotech Group Co., Ltd, Lanzhou Institute of Biological Products Co., Ltd. and Lanzhou Lansheng Blood Products Co., Ltd. will invest over 11 billion RMB in the coming projects.

Biopharmaceutical products including botulinum toxin, collagen Protein, blood products, human serum albumin, intravenous human immunoglobulin (pH4), and human prothrombin complex will be produced in the new workshops and facilities. The P3-level laboratory and P3 workshop projects undertaken by China Biotechnology Co., Ltd. will focus on high-tech laboratory construction for R&D purposes on highly pathogenic microorganism vaccines.

Lanzhou High-tech Zone has always regarded biomedicine as its premium industry via its established industrial cluster. After the completion of the projects above, then the industry can speed up the work process of upgrading traditional vaccines, overall quality improvement and standardization, and provide strong support for building a China first-class biotechnology enterprise in the near future.